Risk Factors Update Summary
- Near-term capital needs increased by $10 million to support hiring, research, regulatory approval, and marketing.
- Accumulated deficit increased from $81.9 million to $91.9 million, raising doubt about continued viability.
- Increased focus on commercialization expenses, including hiring scientists, impacting liquidity and potential financing.
- Quarterly and annual stock price volatility may lead to substantial losses for investors.
- Increased emphasis on the need for additional capital to fund commercialization efforts and product development.
- Challenges in enrolling patients for clinical trials may delay regulatory approvals and increase development costs.
- Potential delisting from Nasdaq due to failure to maintain minimum bid price requirement.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1681682&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.